



# Inborn Errors of Metabolism: Mitochondrial Disease


MODULE 10






# Learning Objectives


- Recognize when to consider mitochondrial disease testing
- Appreciate complexity of testing for mitochondrial diseases
- Understand Modes of Inheritance and associated implications for mitochondrial diseases
- Appropriately utilize counseling for mitochondrial disease evaluation







# Chief Complaint

- 6 yo F with history of developmental delay and ataxia who develops new-onset seizures in the setting of illness.




# Differential Diagnosis - Interactive





# Differential Diagnosis - Ataxia


- Disorders with prominent ataxia
  - Leukodystrophies
    - Metachromatic leukodystrophy
  - Mitochondrial disorders
    - Kearns-Sayre
    - MERRF
    - MELAS
  - Niemann-Pick C
  - Wilson disease
  - GLUT1 deficiency
  - Refsum disease
- Primary ataxias
  - Autosomal dominant
    - Repeat expansions
      - SCA1, 2, 3, 6, 7, ...
    - Conventional variants
      - SCA29, EA2, ...
  - Autosomal recessive
    - Repeat expansions
      - FA
      - CANVAS
    - Conventional variants
      - A-T, AOA1, AOA2, ARSACS, ...






# Differential Diagnosis (Epilepsy)


- Channelopathies-many, among the most seen:
  - KCNQ2, KCNQ3, KCNT1, SCN2A
- Cortical malformations
  - Neuronal migrational disorders: *LIS1*, *ARX*, *DCX*, tubulinopathies, *RELN*,
  - Peroxisomal biogenesis disorders
  - Walker-Warburg syndrome





# Differential Diagnosis (Epilepsy)

- Disorders of amino acid metabolism and transport
  - MSUD; glycine encephalopathy, disorders of serine synthesis and transport; molybdenum cofactor deficiency, isolate sulfite oxidase deficiency
- Organic acidemias
  - Methylmalonic academia, propionic academia, isovaleric acidemia
- Urea cycle disorders
  - OTC, AS, CPS1, ASL, HHH, NAGS




- Vitamin responsive epilepsy
  - Pyridoxine dependent epilepsy, PNPO deficiency, biotinidase deficiency, holocarboxylase synthetase deficiency
- Disorders of membrane transport
  - Glut1
- Disorders of mineral metabolism
  - Menkes
- Mitochondrial encephalopathy



# Differential Diagnosis


| Gene/ Condition                                  | Biochemical Marker                          | Why?  |
|--|---|---|
| Mitochondrial Diseases (too many)                | Lactate, GDF15                              | Decompensation with illness, ataxia, seizures           |
| Pyruvate Dehydrogenase Complex Deficiency (PDCD) | Low Lactate Pyruvate Ratio (Blood)          | Seizures, dystonia, abnormal gait, triggered by illness |
| WWOX (SCAR12)                                    |   | Cerebellar ataxia and seizures                          |
| KCNJ10 (SeSAME)                                  |   | Ataxia, seizures,                                       |
| TPP1/PPT1 (NCL)                                  | TPP1/PPT1 enzyme activity (dried bloodspot) | Ataxia, seizures, motor regression (?)                  |






# HPI, Exam


- 7-year-old female with GDD and ataxia presenting with new onset seizures in the setting of fever.
- Initially, mom noted patient was sleeping very late. When mom tried to wake her, she was moving back and forth and her arm was shaking.
  - Noted: eyes were rolled back and she was unresponsive for a few minutes - unclear how long this lasted. She had urinary incontinence and was admitted for severely altered mental status.
- Pertinent history: Began walking at 16 months but showed unsteady gait at 2 years and frequently falling on uneven surfaces.
  - First evaluated by neurologist at age 3.
  - Was babbling and ambulatory but with clear deficits. Limited sentences but does seem to understand language fully. Makes good eye contact.
  - No hearing concerns. She began to have significant difficulty during illnesses with increased fatigue, worsening gait, and sometimes needing wheelchair at school. She would return to baseline sometime after illness.





# Admission Exam



- **Vitals:** temperature was 101F, BP 120/75, Pulse 158, Resp 20 and Sp02 98%.
- **Gen:** Altered, eyes closed, intermittently moaning, unclear if meningismus
- **CV/Lungs:** warm extremities, cap refill ~2-3 seconds; no respiratory distress
- **Skin:** flushed cheeks, no rash appreciated
- **Abdomen:** No organomegaly
- **Neuro:**
  - **MS:** Stuporous, eyes closed: eyes do not open to pain, intermittently moans in response to sternal rub but does not open eyes, flexion to pain: **GCS 6-7**
  - **CN:** pupils ~3mm and sluggish bilaterally. Negative Dolls eyes. Face symmetric. Tongue midline. Patient not gagged during exam.
  - **Motor:** Minimal spontaneous movement of extremities. Noted: anti-gravity movements of bilateral UE and LE during PIV placement. Hypertonic LE>UE with knees flexed bilaterally. Tight heel cords. No clonus. Upgoing toes bilaterally.
  - **Sensory:** groans unreliable in response to noxious stimuli but does withdraw
  - **DTR:** Arm boards in place bilaterally so unable to elicit biceps reflex, +3 patellar bilaterally and +2 ankle. Tight heel cords. No clonus. Toes upgoing bilaterally.
  - **Coord/Gait:** unable to assess.



# Family History




*What are clues of a  
maternally inherited  
mtDNA disorder?*




# Investigations (Non-Genetic)


- During admission (7 yo):
  - CMP, Ca, Mg, P all normal
  - CBC with **elevated WBC, ANC**
  - CSF: **10 WBC**, <1 RBC, Glu 61, Protein 36
  - Post-admission MRI (not completed inpatient):
    - 1. Mild, diffuse cerebellar volume loss is not significantly changed from previous
    - 2. Punctate focus of T2 hyperintensity in the left periatrival white matter, likely nonspecific gliosis, also unchanged.
- Labs completed during prior workup before admission (3-4 yo):
  - CBC, CMP, CK and AFP were all normal
  - MRI Brain and Spine at time of initial evaluation:
    - 1. Mild diffuse cerebellar volume loss, particularly involving the vermis. Questionable mild volume loss of the medulla. The findings are non-specific, and differentials would include prior/in utero insult as well as metabolic and hereditary disorders.
    - 2. Small focus of gliosis in the left periatrival white matter.
    - 3. Unremarkable rest of the non-contrast brain and spine MRI.




# MRI Findings: Non-Diagnostic




**At age 3 – nonspecific findings**




**At age 7 – mostly unchanged**




Global atrophy including cerebellum is notable





# Investigations (Metabolic)

- Amino acids: non-diagnostic (normal alanine)
- Ammonia: normal on multiple occasions
- Acylcarnitine profile: normal
- Carnitine: normal
- B12/Folate: normal
- NCL enzymes: normal
- Lactate: normal x4, once abnormal to 3.6 during a hospitalization.






# Investigations (Genomic)

- Genome Microarray: Normal
- Prader-Willi/Angelman Syndrome Methylation:
  - No deletions or duplications were detected. Methylation pattern of targeted imprinted genes is normal. Both the maternally and paternally derived copies of the PWS/AS critical region are present.
- ES + Mito:
  - No variants identified in nuclear genes.
  - Mito:

| POSITIVE | Gene    | mtDNA      | Variant             | Heteroplasmy(%)   | Classification     |
|----------|---------|------------|---------------------|-------------------|--------------------|
|          | MT-ATP6 | m.9185 T>C | p.Leu220Pro (L220P) | Approximately 93% | Pathogenic Variant |

Subsequent testing of this individual's mother (GeneDx# 1848544) by Sanger sequencing found that she harbors the m.9185 T>C variant in the MT-ATP6 gene at a much lower level of heteroplasmy. Specifically, the mother's heteroplasmy is estimated to be approximately 30%.



# Exercise Involving Genetic Testing

- The gene result given was:

**POSITIVE**

Gene  
MT-ATP6

mtDNA  
m.9185 T>C


Variant  
p.Leu220Pro (L220P)

Heteroplasmy(%)  
Approximately 93%

Classification  
Pathogenic Variant

- Based on this finding, please break into groups to address the following questions:


- Team A: What is the general understanding of how mtDNA disorders cause disease?
- Team B: What are they canonical diseases caused by mtDNA disorders?
- Team C: What is the mode of inheritance of mtDNA disorders and who should be screened?
- Team D: Do you think this gene is the cause of your patient's symptoms? How will you decide?
- Team E: What biomarkers are used for mitochondrial diseases? How did they apply in this case?




# Mitochondrial Disease: Genetic Causes




- Disease can be caused through Mendelian inheritance
  - Autosomal recessive diseases are most common (e.g. Leigh Syndrome, MNGIE, etc.)
  - Autosomal dominant disease (e.g. POLG progressive external ophthalmoplegia, MFN2 Charco-Marie-Tooth, etc.)
  - And x-linked (e.g. PDHA Pyruvate dehydrogenase deficiency, etc.)
- Disease can be caused through Mitochondrial DNA inheritance (maternal)
  - Mother transmits mtDNA through fertilized egg.
  - mtDNA in sperm is destroyed on entry to egg



Nuclear DNA is inherited from all ancestors.





Mitochondrial DNA is inherited from a single lineage.




# Mitochondria – The Powerhouse of the Cell!




- Most disease is caused by **deficiency** of electron transport chain
- Disease is also caused by **impairment** of mtDNA maintenance, metabolism of substrates, and mitochondrial dynamics






# Limitations of Testing


- For this patient, an exome study + mitochondrial genome was included.
  - This kind of test is considered comprehensive but pushes the limit of what we know clinically.
- Mitochondrial DNA variants may have a “heteroplasmy level” which can be confounding for VUS. Usually having mother tested is helpful (see next few slides).
- Exome limitations apply the same as for other Mendelian disorders.
  - Deep intronic DNA is not tested on the ES for this patient
  - Undiscovered rare genes may not be reported
  - Nuclear genes causing mitochondrial disease may have a broad phenotype and may not be reported on first analysis






# Principles Only Applicable to mtDNA Variants





- Heteroplasmy
  - The mixture of variant mtDNA and “normal” mtDNA in a patient, usually reported by tissue type (e.g. blood, urine, muscle).
- Bottleneck effect
  - Refers to segregation of mtDNA during Oogenesis
- Threshold effect
  - Refers to level of heteroplasmy at which a disease phenotype occurs





# Homoplasm v. Heteroplasmy



# Heteroplasmy: Bottleneck Effect





# Degrees of Heteroplasmy






# Heteroplasmy: Threshold Effect




# Brief Review of mtDNA-Related Diseases




- MT-ATP6 is one of many mtDNA related diseases.
- Most common mtDNA condition is MT-TL1 related Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-like episodes (MELAS)
  - MELAS can be caused by other mtDNA
    - Controversial if nuclear-encoded genes cause MELAS
- Disease from mtDNA variants is (usually) caused by deficiency in providing essential subunits to enzyme complexes of the electron transport chain.







# How to counsel MT-ATP6?

- Range of MT-ATP6 disease is wide.
- Most common phenotypes are Leigh syndrome, NARP (Neuropathy, Ataxia and Retinitis Pigmentosa), non-syndromic sensorimotor neuropathy.
- Our patient had an ataxia/epilepsy/developmental delay phenotype but evolved to MELAS over time.
- Given the complexity of disease/prognosis/screening implications it is critical to have genetic counseling involved.
- Connect family with United Mitochondrial Disease Foundation (UMDF), which is the single largest patient advocacy group for Mitochondrial Diseases.




# Metabolic Stroke

- About 3 years after her initial diagnosis, she presented with focal seizure involving the left face and arm, which did not resolve despite maximal therapy. She was found to have a metabolic stroke:




**Teaching point:**  
Diffusion restriction is not in a defined vascular pattern. This does not look like an ischemic stroke of vascular etiology.

# Metabolic Stroke – Advanced Imaging




- Metabolic stroke-like episode may be caused by abnormally increased blood flow (RelCBF) in otherwise normal vasculature (MRA). In this patient, the right frontal area has increased RelCBF but normal MRA:



Teaching point:


Some patients (particularly MELAS MT-TL1 A3243G patients) have an arginine deficiency. This is thought to cause a relative Nitric Oxide deficiency resulting in abnormal vasoconstriction.

Can treat with Arginine to increase NO production.




# Metabolic Stroke - Recovery

- About 2 years after her initial stroke-like episodes, during which time she had more, she had persistent gliosis and volume loss, but no diffusion restriction in those areas.




Teaching point:


Although initial imaging can look quite devastating at first, sometimes only mild gliosis without encephalomalacia or even complete resolution of lesions occurs.




# Take Home Points




- Patient with static encephalopathy presenting with decompensation or crisis in the setting of illness can be suggestive of mitochondrial disorder.
- There are both maternally inherited and nuclear genes associated with mitochondrial diseases.
- Threshold and bottleneck effect are unique effects seen in maternally inherited mitochondrial diseases.
- MRI can have classic findings, such as stroke-like episodes or Leigh syndrome (bilateral basal ganglia lesions), but sometimes may be non-specific.






# Suggested Reading

- Parikh, S., Goldstein, A., Koenig, M. *et al.* Diagnosis and management of mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society. *Genet Med* **17**, 689–701 (2015).
- Ganetzky RD, Stendel C, McCormick EM, Zolkipli-Cunningham Z, Goldstein AC, Klopstock T, Falk MJ. MT-ATP6 mitochondrial disease variants: Phenotypic and biochemical features analysis in 218 published cases and cohort of 14 new cases. *Hum Mutat.* 2019 May;40(5):499-515. PMID: 30763462; PMCID: PMC6506718.
- Taylor, R., Turnbull, D. Mitochondrial DNA mutations in human disease. *Nat Rev Genet* **6**, 389–402 (2005).
- Parikh, S., Goldstein, A., Karaa, A. *et al.* Patient care standards for primary mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society. *Genet Med* **19**, 1380 (2017).






# Acknowledgements

## Leads:

- Kuntal Sen (CNMC)
- Louis Dang (UM)

## Core members:

- Amitha Ananth (UAB)
- Andrea Gropman (CNMC)
- Education
  - Rachel Gottlieb-Smith (UM)
  - Jeff Strelzik (CNMC)



## Committee members:

- Daniel Calame (Baylor)
- Divakar Mithal (Northwestern)
- Christa Habela (Hopkins)
- Kristin Baranano (Hopkins)
- Lisa Emrick (Baylor)
- Margie Ream (Nationwide)
- Julie Ziobro (UM)

## Additional Members:

- Alexa Taylor (CNMC)